Q-omics provides the consensus-scored CFL1P7 profile across patient tissues and cancer cell-line models. CFL1P7 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, CFL1P7 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, CFL1P7 RNA expression shows 9,501 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight UCS, BRCA, and CCRCC as cancer lineages where CFL1P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFL1P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFL1P7 survival associations across molecular data types. CFL1P7 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFL1P7 RNA expression–survival associations across cancer types. High CFL1P7 expression shows unfavorable associations in PAAD, KIRP, STAD and OV, but favorable associations in UCS and CESC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .012). Together, the overview and detailed table identify UCS as the clearest survival context for CFL1P7 RNA expression.
This table summarizes CFL1P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CFL1P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFL1P7 shows lower tumor expression in THCA and higher tumor expression in BRCA, UCEC, LUSC, STAD and KICH. The BRCA box plot shows higher CFL1P7 RNA expression in tumor versus normal tissue (log2 FC = +0.026, t-test p = .005).
This table shows molecular features associated with CFL1P7 in patient tissues and cancer cell lines. In patient samples, CFL1P7 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
